Sugi Predict

Sugi Predict / Compounds / SCHEMBL361871

SCHEMBL361871

SCHEMBL361871

CC(C)(C)OC(=O)NC1(c2ccc(C(=O)Cc3ccccc3)cc2)CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 4/20 0.42
▸ AKT2 P31751 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SRD5A2 P31213 2/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ STS P08842 1/20 0.38
▸ GRIN2B Q13224 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ CTSS P25774 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ NPFFR1 Q9GZQ6 1/20 0.36
▸ NPFFR2 Q9Y5X5 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ S1PR5 Q9H228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12583792 0.98 L3MBTL1 (0.41) AKT1AKT2L3MBTL1MAPTSRD5A2
SCHEMBL12376145 0.95 MAPT (0.43) AKT1L3MBTL1MAPTSRD5A2CA12
SCHEMBL12133148 0.89 RORC (0.39) AKT1AKT2KMT2ACTSSCTSK
SCHEMBL10167166 0.87 L3MBTL1 (0.39) AKT1L3MBTL1MAPTSRD5A2CA12
SCHEMBL538373 0.87 L3MBTL1 (0.39) AKT1L3MBTL1MAPTSRD5A2CA12
SCHEMBL10226688 0.87 L3MBTL1 (0.39) AKT1L3MBTL1MAPTSRD5A2CA12
SCHEMBL512719 0.87 L3MBTL1 (0.39) AKT1L3MBTL1MAPTSRD5A2CA12
SCHEMBL12133454 0.85 GPR119 (0.39) AKT1AKT2KMT2ACTSSCTSK
SCHEMBL12133598 0.84 AKT1 (0.45) AKT1AKT2PPARGPPARDPPARA
SCHEMBL10226581 0.84 KDM4E (0.37) AKT1L3MBTL1MAPTSRD5A2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102791708-B The inhibitor of AKT activity ALMAC DISCOVERY LTD. (GB) 2016-03-02 — — CN disclosed
EP-2593451-B1 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER IP GMBH (DE) 2015-08-19 — — EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 — — EP disclosed
US-8975265-B2 Substituted imidazo[1,2-a]pyrimidines and —pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-10 — — US disclosed
US-8691825-B2 Inhibitors of AKT activity MERCK SHARP & DOHME CORP. (US) 2014-04-08 — — US disclosed
US-8691825-B2 Inhibitors of AKT activity MERCK SHARP & DOHME CORP. (US) 2014-04-08 — — US disclosed
US-20130287763-A1 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR MERCK SHARP & DOHME CORP. (US) 2013-10-31 — — US disclosed
US-20130287763-A1 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR MERCK SHARP & DOHME CORP. (US) 2013-10-31 — — US disclosed
US-8536193-B2 Inhibitors of AKT activity MERCK SHARP & DOHME CORP. (US) 2013-09-17 — — US disclosed
US-8536193-B2 Inhibitors of AKT activity MERCK SHARP & DOHME CORP. (US) 2013-09-17 — — US disclosed
US-20110288090-A1 Inhibitors of AKT Activity MERCK SHARP & DOHME CORP. 2011-11-24 — — US disclosed
US-20110160183-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2011-06-30 — — US disclosed
US-20110082135-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2011-04-07 — — US disclosed
WO-2010088177-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-08-05 — — WO disclosed
US-20090253734-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. 2009-10-08 — — US disclosed
US-7576209-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2009-08-18 — — US disclosed
US-7576209-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2009-08-18 — — US disclosed
US-20080161317-A1 Inhibitors of Akt activity MERCK SHARP & DOHME LLC 2008-07-03 — — US disclosed
US-20080161317-A1 Inhibitors of Akt activity MERCK SHARP & DOHME LLC 2008-07-03 — — US disclosed
WO-2008070016-A2 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2008-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161317-A1 Inhibitors of Akt activity PIK3CD, PIK3CA, PIK3CG AKT1 12/4885AKT2 4/4885L3MBTL1 2547/4885
US-20110160183-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3CG AKT1 12/4885AKT2 4/4885L3MBTL1 2547/4885
US-20130287763-A1 COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR IGF1R, IGFBP1, IGFBP2 AKT1 65/4885AKT2 28/4885L3MBTL1 1697/4885
US-20110082135-A1 INHIBITORS OF AKT ACTIVITY PIK3CA, AKT1S1, AKT1 AKT1 3/4885AKT2 5/4885L3MBTL1 1517/4885
US-20090253734-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3CG AKT1 12/4885AKT2 4/4885L3MBTL1 2547/4885
US-20110288090-A1 Inhibitors of AKT Activity PIK3CD, PIK3CA, PIK3CG AKT1 9/4885AKT2 5/4885L3MBTL1 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.